two acellular pertussis vaccines , a mono-component toxoid of pertussis toxin and a two-component vaccine containing both the toxoid and filamentous haemagglutinin , were used for primary immunization of infants 5 1/2 to 10 months of age in two clinical trials in sweden .
C0042210
vaccine
C0040555
toxoid